AN OPTIMAL REGULATORY MIX FOR METHAMPHETAMINE PRECURSORS?

Similar documents
Methamphetamine - Oregon Fact Sheet

Understanding how a high-level drug trafficking network in Australia adapts to changes in its drug supply

PRODUCTS: All products containing ephedrine (EPH) and pseudoephedrine (PSE). (IC )

Multnomah County s biggest drug bust ever on February 23rd, 2017 This bust of more than 100 pounds of meth highlights a new trend in drug

Kentucky Pharmacist Opinions of the Potential Reclassification of Pseudoephedrine as a Legend Drug. Kathleen E. Monson PharmD/MPA Candidate 2013

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis. February 2018

REVISED ELEMENTS - PROPOSED BY THE UNGASS BOARD TO THE CND FOR FURTHER CONSIDERATION - STATUS 4 November 2015

A Preliminary Report on Trends and Impact. Mike McGrath. January Montana Attorney General

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis

Informal meeting of the Justice and Home Affairs Ministers Sopot July 2011

Legalization, Regulation and Restriction of Access to Cannabis

and practice: Three AIC examples Dr Adam Tomison

ANNEX AU PLAN OF ACTION ON DRUG CONTROL AND CRIME PREVENTION (AUPA) ( ) IMPLEMENTATION MATRIX

Home Model Legislation Public Safety and Elections. Methamphetamine Reduction Act

Cannabis Legalization in Alberta

Submission to the Misuse of Drugs Amendment Bill September Society and its Role and Functions. 29 September 2010

Components of good drug policy

SB 484 Prescription Pseudoephedrine Eliminating California Methamphetamine Production

Act on Narcotic Drugs and Psychotropic Substances and Precursors thereof

Yukon s Proposed Framework for. Legalized Cannabis 30 GRAMS MINIMUM AGE

Legalization of Cannabis: The Way Forward

Oregon Narcotics Enforcement Association. January 15, Media Information

Author: Laura A Scott and Lucy Burns, National Drug and Alcohol Research Centre, University of New South Wales

Launch of the INCB Annual Reports 2015

Legalization and Regulation of Recreational Cannabis PRESENTATION LPPANS NOVEMBER 22, 2017

Organization of American States OAS Inter-American Drug Abuse Control Commission CICAD. Multilateral Evaluation Mechanism MEM.

Resolution 59/8 Promotion of measures to target new psychoactive substances and amphetamine-type stimulants

Controlled Substances

Office of National Drug Control Policy

B.C. Cannabis PRIVATE RETAIL LICENSING GUIDE Applications and Operations

History & Epidemiology of Exposure to Methamphetamine Contamination in Homes and Clandestine Labs

Managing Access to Pseudoephedrine ii

Developing a drug monitoring system for New Zealand: IDMS

Plain Packaging of Tobacco Products FAQ

Creating a Sense of Urgency Youth and Young Adult Drug Use

Taking Stock of the 2009 PoA Research and Trend Analysis Branch

TN Opioid Program. Erica Schlesinger, Pharm.D

COMBATING THE ILLICIT TRADE OF CIGARETTE AND TOBACCO PRODUCTS ANTI ILLICIT TRADE CONFERENCE CAPE TOWN, SOUTH AFRICA 9 11 NOVEMBER 2015

Marijuana in Washington, DC. Arrests, Usage, and Related Data

Prescription Drug Abuse Task Force Rx Report Card

Police Role in the Community. Chapter 11 James J. Drylie, Ph.D.

Searches: Consent 9; Warrant: 44. Arrests: Drug 179; Non-Drug: 8. Weapons Seized: Handgun 3; Long Gun: 14. Meth Lab Seizures: Labs 2; Dump Sites - 0

ILLICIT DRUG TRADE. Future-oriented policing projects

High and Dry: An Economic Analysis of Drug Use in Dry Counties

Changes in indicators of methamphetamine use and. property crime rates in Oregon

Using Prescription Drug Monitoring Program Data to Advance Prevention Planning

Scottish Health Action on Alcohol Problems. Alcohol (Licensing, Public health and Criminal Justice) (Scotland) Bill

LAW ON PREVENTION AND SUPPRESSION OF THE ABUSE OF NARCOTIC DRUGS

Federal Resources for Research on Drugs and Crime. Meeting of Caribbean National Observatories on Drugs August 5, 2009

Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield and

Methamphetamine: A Devastation in Indian Country and Funding Needs Dave Heisterkamp Sylvia Wirba Wagenlander & Heisterkamp LLC December 7, 2016

Managing Access to Pseudoephedrine / Potential Impacts of a Prescription-Only Policy versus Real-Time Stop Sale Technology

North Carolina, like the rest of the nation, has been experiencing

Changes in Attitudes to Drug Diversion Initiatives

FAQs Kahnawà:ke Cannabis Control Law

QUESTIONNAIRE. Submission Information. Information for follow-up purposes. Publishing on the UNODC website

Colorado s Cannabis Experience Doug Friednash

2014 Key Australian findings: psychostimulant drug market

Public consultation for the 2016 evaluation of the EU Drugs Strategy and Action Plan on Drugs

Cannabis Regulation in Canada:

DRAFT OUTCOME DOCUMENT (14 JANUARY 2016) UNGASS

What should be done to ensure the safety, efficacy and quality of medicines?

Organization of American States OAS Inter-American Drug Abuse Control Commission CICAD. Multilateral Evaluation Mechanism MEM.

Written Brief to the Standing Committee on Health

MARIJUANA LEGALIZATION. INITIATIVE STATUTE.

Measuring Illicit Tobacco Markets

Illicit drug markets in Asia: Focus on East and SE Asia

Drug Threat Summaries of Designated Areas

WikiLeaks Document Release

Legalization of Cannabis- Overview

SACRAMENTO DEA: METHAMPHETAMINE. Intelligence Analyst Matthew S. Kregor

Requirements of the International Drug Control Conventions, Catherine Muganga Legal Officer, UNODC Feb 2015

ADOPTED BY THE GENERAL ASSEMBLY, THE ECONOMIC AND SOCIAL COUNCIL (ECOSOC) AND THE COMMISSION ON NARCOTIC DRUGS (CND).

COUNCIL OF THE EUROPEAN UNION. Brussels, 7 July /04 CORDROGUE 59

Legalization of Recreational Cannabis

The Home Office Proposals to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001 January 2018

CANNABIS IN YOUR COMMUNITY. A Presentation to CPAA Conference May 2017

Key findings for drug use patterns & drug markets

Regulatory Options for State Cannabis Legalization: What Prevention Needs to Know

NIJ s Drugs and Crime Research Portfolio

Interstate dispensing : A case for uniform, intuitive legislation

FACT SHEET 1 IRAN (ISLAMIC REPUBLIC OF)

Policy Planning and Choice: TOOLKIT. Guide to Feasible Interventions. Adapted from:

Does information matter? The effect of the meth project on meth use among youths Journal of Health Economics 29 (2010)

Cannabis Legalization August 22, Ministry of Attorney General Ministry of Finance

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

Global market for synthetic stimulants expanding

Pennsylvania Prescription Drug Monitoring Program Trends,

Cannabis Legalization and Regulation in British Columbia Discussion Paper

Psychoactive Substances (Increasing Penalty for Supply and Distribution) Amendment Bill

DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT

The Criminal Justice Response to Opioid Trafficking in Michigan

Drug Money: the illicit proceeds of opiates trafficked on the Balkan route. Executive summary

QUESTIONNAIRE. Submission Information. Information for follow-up purposes. Head of International Drug Policy, Home Office

Greens NSW Drug Regulation and Harm Minimisation Policy

Report of the International Narcotics Control Board on Follow-up to the Twentieth Special Session of the General Assembly

Addis Ababa, ETHIOPIA P. O. Box 3243 Telephone Cables: OAU, ADDIS ABABA

DEA: Combating the Supply

2016 National Drug Price and Purity Data

Crime, persistent offenders and drugs: breaking the circle A Cumberland Lodge Conference 6 8 th June 2003

Transcription:

AN OPTIMAL REGULATORY MIX FOR METHAMPHETAMINE PRECURSORS? Janet Ransley Griffith University

Responding to methamphetamine problems How should governments respond to the problem of domestic, illicit production of methamphetamine? NZ PM John Key: The government is adopting a multi-pronged approach to fighting this dangerous scourge by cracking down on precursors, breaking the supply chain, better routes into treatment, supporting families and community, and strengthening leadership and accountability. 8 Oct 2009

Developing an optimal response What are the available policy and regulatory options? What evidence is there about their usefulness, costs and side effects? Is there enough evidence to suggest an optimal response, and if so, what is it?

Why precursor regulation? About 90% of Australian ATS produced locally Methamphetamines produced in clandestine laboratories, using mainly locally obtained precursors Precursors mainly diverted from licit uses, especially pharmacy sales International drug control policy has dictated law enforcement and regulatory approaches to controlling precursors

What options have been tried? 1. Increased border and domestic policing of ATS and precursors international 2. Restrict pseudoephedrine sales (PSE) quantities, packaging, product placement etc all Australia & USA & NZ 3. Restrict sales of PSE to pharmacy only all Australia & some USA states & NZ 4. Require logging of sales & proof of identity some states eg Vic 5. Require centralised electronic monitoring & reporting of sales Queensland, Oklahoma, Kentucky 6. Restrict PSE to prescription only Oregon 7. Restrict PSE to prescription only & limit prescribing proposed NZ 8. Ban PSE products Mexico

Assessing what works? At what costs? What is success? Reduced illicit methamphetamine use/demand? Reduced local illicit methamphetamine production/supply? Unintended consequences? How is this measured? Prevalence surveys, hospital admissions, treatment demands Detection of clandestine laboratories/ STLs Identification & measurement of side-effects Are the outcomes worth the costs?

Project STOP evaluation Policy options for regulating precursors 1. Do nothing new continue current approaches 2. Increase reactive policing 3. Ban PSE products 4. Restrict PSE to prescription only 5. Require ID and monitor sales Project STOP What do we know about what works best, in what circumstances, & at what cost?

Option 1 current approaches Federal government criminalises illicit: trafficking, cultivation, sale, manufacture, import, export, possession of ATS, pre-trafficking in precursors, harms caused to children Criminal Code 1995 And regulates licit ATS and their precursors: National Diversion Prevention Strategy Rescheduled ATS and precursor products to prescription or pharmacy sales only Therapeutic Goods Act 1989

Option 1 current approaches (cont) States and territories also Criminalise pre-trafficking etc Regulate how pharmacies sell products, labelling, storage & identity verification But variations in criminal offences, penalties & in regulatory approaches Voluntary, cooperative & enforced cooperative models Complex, fragmented policy & regulatory environment

Variations in current state regulatory approaches to precursors Restrict quantity, storage, sale by pharmacist, dispensing, labelling Qld (Enforced) Vic (Co-op) Tas (Vol) Yes Yes Yes Pharmacists required to take reasonable steps to identify purchaser, assess validity of use, report suspicions to police Yes Yes No Pharmacists required to obtain photo ID, enter sales on register, send to police, make available to health regulator Yes No No

Option 2 increased reactive policing Multiplicity of agencies Variations between jurisdictions Increasing involvement of organised crime Resource intensive What works best? Neighbourhood-wide approaches? Problem-oriented policing? Partnership approaches? Crackdowns? Raids? Hotspot directed patrols? Lack of an evidence base on what works

Option 3 ban PSE products Substitute products not as effective for licit use Consumer inconvenience Health & economic costs from less effective treatments May shift illicit supply to importation of PSE Likely to strengthen involvement of organised crime

Option 4 make PSE prescription only Substitute products not as effective for licit use Consumer inconvenience Shifts decision-making burden from pharmacist to medical practitioner Health & economic costs from less effective treatments/ more doctor visits May shift illicit supply to importation of PSE May strengthen involvement of organised crime

Option 5 improve monitoring Project STOP Data recording & decision-making tool that tracks PSE sales in real time Records buyer ID, product, date, location, sale or denial of sale, duress Accessible by police, health regulators, pharmacy guild Has mapping & intelligence functions Can be adapted to other products in >95% Qld pharmacies, 63% nationally Funded for national roll-out, but inconsistent regulatory frameworks across states Makes pharmacists burden bearers for reducing PSE diversion & imposes significant costs

What is the evidence on the options? First wave USA federal restrictions on large scale PSE led to fewer clan labs, meth-related arrests, meth-related hospitalisations & treatment, & lower purity But restrictions on small scale PSE had little impact Cunningham et al 2009 Data on price & arrestee use show little change in demand from federal restrictions Reuter et al 2003 So Combat Meth Act 2005 imposed retail level restrictions

The evidence (cont) US state regulation on retail PSE varies between: No extra state regulation Restrictions on display, quantities, require ID 41 states Pharmacy only sales 11 states Prescription only sales Oregon Centralised/electronic monitoring Oklahoma, Kentucky

The evidence (cont) US outcomes? Clan lab detections declined nationally after Combat Meth Act, virtually eliminated in Oregon, 90% reduction in Oklahoma Detections now rising again, and since 2008, an increased flow from Mexico, despite its PSE ban Increase in labs much smaller in Oregon than most other states But small scale producers smurfing & crossing borders to circumvent state regulation Shifting patterns/methods of production Slight decrease in prevalence, but stable treatments Overall, domestic production will increase in the short term (NDIC 2009)

Implications for Australia? Meth market is highly adaptive, and can switch between imports & domestic production, & changed methods of production & supply State differences enable circumvention of regulation Prescription only PSE has best effect on clan labs, but this is an imperfect measure, and costly Improved monitoring on its own not enough requires regulation enforcing compliance to be effective What is the best regulatory environment for monitoring via Project STOP?

An enforced regulation approach Shift to more coercive regulatory enforcement style

Implications Project STOP may be able to achieve similar results to options 3 & 4, but for less cost & inconvenience But Project STOP on its own may not be enough regulatory context matters Shift to enforced rather than voluntary cooperation Consistency between jurisdictions Comprehensive policy, to avoid easy switches to other suppliers/ methods of production/drugs